По следам научно-практической конференции «Онкология будущего»

1. Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2017 (morbidity and mortality) Moscow, 2018.

2. Mammary cancer. Clinical guidelines of the Ministry of Health of the Russian Federation, 2021. https://cr.minzdrav.gov.ru/schema/379_4

3. F. Cardoso et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of Oncology. https://doi.org/10.1016/j. annonc.2020.09.010

4. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 4. 2021.

5. Stenina M.B., Zhukova L.G., Koroleva I.A., Parokonnaya A.A., Semiglazova T. Yu., Tyulyandin S.A. et al. Practical recommendations for drug treatment of breast cancer. Malignant tumors: RUSSCO Practice Guidelines #3s2, 2020 (volume 10). 09.

6. Nadine M. Tung, Judy C. Boughey, Lori J. Pierce et al., Management of hereditary breast cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline. J Clin Oncol. 2020; https://doi.org/10.1200/jco.20.00299

7. Clinical guidelines of the RPOM «Gold Standard» for the diagnosis and treatment of breast cancer. 2021.

8. Liquan Wang, Shuyan Gao, Dianfang Li et al., CDK4/6 inhibitors plus endocrine therapy improve overall survival in advanced HR+/HER2-breast cancer: A meta-analysis of randomized controlled trials. Breast J. 2019; 00: 1–5, https://doi. org/10.1111/tbj.13703

9. Litton J.K., Rugo H.S., Ettl J., Hurvitz S.A., Goncalves A., Lee K.H. et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018; 379 (8): 753–763. DOI: 10.1056/NEJMoa1802905.

10. P Schmid, S Adams, HS Rugo, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med, 379 (2018), pp. 2108–2121 https://doi. org/10.1056/nejmoa1809615

11. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10; 377 (6): 523–533. DOI: 10.1056/NEJMoa1706450.

12. Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Lida A Mina, Sami Diab, Natasha E Woodward, Rinat Yerushalmi, Annabel Goodwin, Joanne L Blum, Miguel Martin, Ruben G W Quek, Iulia Cristina Tudor, Helen Bhattacharyya, Eric Gauthier, Jennifer K Litton, Wolfgang Eiermann. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy, JNCI Cancer Spectrum, Volume 4, Issue 1, February 2020, pkz085, https://doi. org/10.1093/jncics/pkz085

13. Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Gonçalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roché H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov; 31 (11): 1526–1535. DOI: 10.1016/j.annonc.2020.08.2098.

14. Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019 Apr 1; 30 (4): 558–566. DOI: 10.1093/annonc/mdz012.

15. Instructions for the medical use of the Talzenna medicinal product (registration certificate of the medicinal product for medical use LP 006116 dated 02.28.2020, change in the instruction from 10.26.2020).

16. Minutes of the meeting of the commission of the Ministry of Health of the Russian Federation on the formation of lists of drugs for medical use and the minimum range of drugs required for the provision of medical care dated August 4, 2021. https://minzdrav.gov.ru/special/ministry/61/10/stranitsa 858/protokol-zasedaniya-komissii-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-po-formirovaniyu-perechney-lekarstvennyh-preparatov-dlya-meditsinskogo-primeneniya-i-minimalnogo-assortimenta-lekarstvennyh-preparatov-neobhodimyh-dlya-okazaniya-meditsinskoy-pomoschi-ot 4-avgusta 2021-goda

17. Draft decree of the Government of the Russian Federation on the approval of changes to the lists of medicinal products for medical use and the minimum range of medicinal products required for the provision of medical care. https://minzdrav. gov.ru/ministry/61/10/stranitsa 858/proekt-rasporyazheniya-pravitelstva-rossiyskoy-federatsii-ob-utverzhdenii-izmeneniy-vnosimyh-v-perechni-lekarstvennyh-preparatov-dlya-meditsinskogo-primeneniya-i-minimalnogo-assortimenta-lekarstvennyh-preparatov-neobhodimyh-dlya-okazaniya-meditsinskoy-pomoschi 2022

18. https://minzdrav.gov.ru/documents/7025-federalnyy-zakon 323-fz-ot 21- noyabrya 2011-g